Skip to content

A Real-World Retrospective Cohort Study of Salvia and Notoginseng Formula for the Treatment of Carotid Plaque

A Real-World Retrospective Cohort Study of Salvia and Notoginseng Formula for the Treatment of Carotid Plaque

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025000264
Enrollment
Unknown
Registered
2025-02-14
Start date
2025-02-21
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carotid plaque

Interventions

Control group:none
Exposure group:Danshen Sanqi Decoction

Sponsors

The Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Referencing the criteria from the "Chinese Expert Consensus on the Ultrasound Evaluation of Vulnerable Carotid Plaque (2023 Edition)" and the "Chinese Consensus on the Diagnosis and Treatment of Cervical and Cerebral Atherosclerosis (2017 Edition)": Carotid atherosclerosis includes increased carotid intima-media thickness (IMT) carotid plaque stenosis and even occlusion. Increased IMT is defined as IMT = 1.0 mm. Carotid plaque is defined as focal IMT = 1.5 mm or encroachment into the lumen = 0.5 mm or an increase of more than 50% compared to the surrounding IMT values. Carotid stenosis is defined as a degree of stenosis = 50% and even occlusion. Increased IMT and carotid plaque are also defined as early-stage carotid atherosclerosis. (2) Age greater than 18 years with no gender restrictions. (3) Complete electronic medical record data

Exclusion criteria

Exclusion criteria: (1) Patients in the acute phase of cardiovascular and cerebrovascular diseases and high-risk patients with indications for interventional or surgical treatment. (2) Patients with secondary dyslipidemia due to other causes (such as nephrotic syndrome cholestatic jaundice etc.). (3) Pregnant and breastfeeding women. (4) Patients with mental disorders who cannot cooperate well. (5) Patients with severe heart disease severe neurosis or significant dysfunction of the heart liver or kidneys confirmed by examination. (6) Patients with severe primary diseases of the endocrine system hematopoietic system liver or kidneys malignant tumors or mental illness. (7) Patients with uncorrected hyperthyroidism or hypothyroidism; patients with nephrotic syndrome diabetes or acute hepatobiliary diseases. (8) Patients who have suffered from severe cerebrovascular accidents heart diseases severe trauma or major surgeries within the past 6 months as well as those with other primary diseases that are unstable and have a poor prognosis.

Design outcomes

Primary

MeasureTime frame
Carotid plaque;

Countries

china

Contacts

Public ContactLi yunlun

The Affiliated Hospital of Shandong University of Traditional Chinese Medicine

li.yunlun@163.com13869102760

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026